Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT03788252
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- Gumi Cha Medical Center
- Registry
-
NCT03788252
-
- Other papers using this trial's data
- Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY study
- Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03788252. Randomized; no masking; primary purpose prevention. Start 2018-11-23 (actual); primary completion 2020-07-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease
- Acronym
- RECOVERY
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Renamezin
- Lead sponsor
- Gumi Cha Medical Center
Record details
- Record id
cardio:ct-nct03788252- Content hash
7404b7b7414a685043178b2f238b96cb84a13fba9a063c730120e5e370187c26